September 2026 Research Update

This month added a clearer picture that setmelanotide (a medicine that targets appetite pathways) can have very different results from one person with Bardet-Biedl syndrome to another. Across an adult case report and a 2-child case series after kidney transplant, some people had meaningful weight and hunger reductions while another had only modest or temporary changes. Where kidney outcomes were reported, graft function and estimated kidney function stayed stable during treatment, although these are small reports that cannot predict what will happen for most patients. [1] [2]

In the pediatric kidney transplant case series, one teenager had decreases in weight, body mass index, and reported hunger over follow-up, along with improved blood sugar and lipids, while the younger child had an early drop in body mass index that later rose again even as hunger scores improved. Both children were reported to have stable transplant kidney function and stable cyclosporine levels during setmelanotide use, with skin darkening noted as a side effect. This highlights that appetite may improve even when weight change is limited, and that responses may depend on individual factors that are not yet well understood. [2]

The adult case report described sequential use of liraglutide (a GLP-1 medicine used for weight and diabetes) followed by setmelanotide, with additional weight loss after switching and reported improvements in liver tests and a urine marker of kidney stress (albumin in the urine), while overall kidney filtration stayed stable. The paper also noted that small interventional studies in the literature have reported similar directions of change for weight-related measures and some liver and kidney markers, but those results were not newly generated in this single-patient report. Taken together, the new information this month mainly strengthens the idea that setmelanotide may affect more than weight alone in some individuals, but the evidence remains early and variable. [1]

For patients and families, these reports add detail about what has been observed in day-to-day care: setmelanotide may reduce hunger and weight for some people with Bardet-Biedl syndrome, but the size and durability of the change can differ a lot between individuals. This evidence is still early because it comes from one adult case and two children, so it cannot tell how often these outcomes happen or who is most likely to benefit. The kidney-transplant cases are also a reminder that researchers are paying attention to kidney-related safety and lab values in special situations, but larger and longer studies are needed to know what these findings mean for most patients over time. [2] [1]

This month strengthened a practical point: broad genetic testing can often find a clear molecular explanation for Bardet-Biedl syndrome, especially in families where parents are related. In a 26-person Iranian cohort with suspected BBS, researchers reported finding causative or possibly causative gene changes (variants) in every participant, spread across many BBS-related genes, although some were classed as of uncertain significance, meaning their role is not yet confirmed. The pattern also showed that copy-number changes (missing gene pieces) and even more than one genetic diagnosis can occur, which helps explain why symptoms can vary so widely between people. [3]

The study reported variants across 13 genes, with several genes appearing repeatedly (including BBS2, BBS5, BBS10, BBS12, and CEP290). Most variants were homozygous, matching the high rate of consanguinity reported in the families, and one person had a separate hearing-loss condition due to a different gene (a dual molecular diagnosis). The authors also described finding a deletion affecting part of the BBS2 gene, which is the type of change that may be missed if testing only looks for single-letter DNA changes. [3]

For families, this study mainly adds confidence that modern genetic testing can provide an explanation for BBS in many people, and that sometimes it can uncover more than one genetic reason for a person s symptoms. This matters now mostly for understanding the diagnosis and why features can differ from one person to another, rather than changing symptoms directly. What remains uncertain is how well these results apply outside this specific population and how to interpret variants of uncertain significance, which the authors noted without functional lab confirmation. [3]

This month included an early, hypothesis-building signal that Bardet-Biedl syndrome may be linked to a distinct pattern in the oral microbiome (bacteria in the mouth) and small molecules measured in saliva and gum fluid. The study combined 10 people with BBS or Alstrom syndrome and 23 relatives who carry one copy of a related gene change into a single group; this group partly separated from obesity and healthy comparison groups based on combined microbiome and metabolite patterns, with substantial overlap, and the authors suggested the differences were not explained by body weight alone. Because the work was small and cross-sectional, it cannot show cause and effect, but it helps map biological pathways researchers may track in future studies. [4]

Compared with controls, the combined BBS/Alstrom and carrier group showed higher levels of several bacterial groups (including Enterococcus and Eikenella) and lower levels of Lactobacillus, along with shifts in measured chemicals connected to amino acid, fatty acid, and carbohydrate metabolism. The researchers also reported that relationships between certain bacteria and certain metabolites were more structured in gum fluid and broader in saliva, and that an integrated multi-omics signature could be identified across these sample types. These results point to coordinated changes across bacteria and metabolism, but the study did not test whether changing oral health, diet, or treatments would change these patterns. [4]

For patients and caregivers, this study mainly matters as early research rather than something used in care today. It helps clarify that researchers are looking beyond genes alone and testing whether body metabolism in ciliopathies may leave detectable fingerprints in easy-to-collect samples like saliva or gum fluid. What is still uncertain is whether these oral patterns relate to symptoms, predict health outcomes, or could ever be used as a helpful test, since the study was small and did not follow people over time. [4]

This month included a reminder that not every medical problem in someone with Bardet-Biedl syndrome is automatically caused by BBS itself. One reported patient had severe high blood pressure and low potassium that were traced to primary hyperaldosteronism from a one-sided adrenal adenoma, and symptoms improved after the adrenal gland tumor was removed. Because this is a single-person report, it cannot show how common this is in BBS, but it documents a specific, testable explanation for difficult-to-control blood pressure in this individual. [5]

For families, this case mainly adds awareness that, in at least one person with BBS, severe blood pressure problems had a separate endocrine cause that improved after targeted treatment. It does not prove that BBS raises the chance of adrenal tumors, and the authors noted the overlap could be coincidental. The value here is documentation: it expands the list of possibilities researchers and clinicians may consider when unusual combinations like high blood pressure plus low potassium occur, but it does not change routine care on its own. [5]